Dr. Reddy’s Laboratories (DRREDDY) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition of Nicotinell and related brands, including a global NRT portfolio, strengthens the consumer healthcare OTC business and aligns with the strategy to expand in OTC wellness products across 30+ countries outside the US.

• The acquired brands are market leaders, with Nicotinell holding leading positions in 14 of the top 17 markets and among the top 15 OTC brands in Europe.

• The deal provides access to established brands with strong customer loyalty and global reach, serving as an anchor for further OTC platform growth.

• The acquisition supports ambitions to build a global OTC platform and leverage established customer relationships for cross-selling and future product additions, especially in Asia.

Financial terms and conditions

• Total consideration is GBP 500 million: GBP 458 million upfront cash and up to GBP 42 million in earn-outs or performance-based contingent payments due in 2025 and 2026.

• The portfolio generated GBP 217 million in revenue in 2023 and is described as highly profitable and margin-accretive, with expected EBITDA margins at or above 25%.

• The acquisition will be funded through internal accruals.

Synergies and expected cost savings

• Main synergies expected from leveraging the platform to introduce additional products and expand into new markets, such as India and China.

• Access to key customers and retailers will facilitate shelf space for other products and enhance operating leverage.